Cell Expansion - A Big Move in Cancer Treatment!

Cell expansion is defined as the production of daughter cells which arise originally from the single cell. Cell expansion is beneficial either therapeutically as drug screening tools or for core research purposes. Currently, cell expansion is majorly used for stem cells expansion which are transplanted in patients with blood cancer. Cell expansion also has a potential to be used in various diseases linked with genetic defects such as Parkinson’s diseases or Alzheimer’s disease. The cell expansion market can be differentiated into various segments on the basis of type of cells used for expansion and by applications. On the basis of type of cells used for expansion, the cell expansion market has been differentiated into three classes which include:

• Human Cells

• Animal Cells

• Plant Cells

Human cells capture the major share of the cell expansion market on the basis of cell type. These

cells are used for therapeutic applications for curing various types of cancers and genetic disorders. Human cells market could further be segmented into two classes which include stem cells and differentiated cells. Animal cell expansion on other hand is used for very less therapeutic applications however; plant cell expansion is currently under research activities for therapeutic applications. On the basis of applications, the cell expansion market has been classified as follows:

• Stem cell research

• Regenerative drugs

• Biotechnology and biopharmaceuticals

• Clinical diagnostics

Stem cell research dominates the cell expansion factors. Extensive use of stem cells for therapeutic cancer and genetic diseases involves the extensive cell expansion procedure. Biotechnology and biopharmaceutical research also involves the cell expansion to a high extent. Recently, GE Healthcare has launched a cell expansion technology, Xuri W25 that is designed to develop T-cell and is used for performing T-cell therapies. Cell expansion based cellular regenerative medicines are used majorly for developing medicines for cardiovascular and neurological diseases.

Get a Sample Copy of Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=9037

Small Molecule Targeted Cancer Therapy Market to Lead in 2016!

Small molecule targeted cancer therapies are drugs designed to block the growth of cancerous cells. Conventional cytotoxic medications and chemotherapies usually destroys rapidly dividing cancer cells by inhibiting cell division process. However, small molecule targeted therapies destroys cancerous cells with fewer side effects and high precision. Small molecule targeted cancer therapies can be used for the treatment of various cancers such as prostate cancer, multiple myeloma, breast cancer, lymphoma, melanoma and other cancers.

Targeted cancer drugs are broadly classified as follows:

• Small Molecules
• Monoclonal Antibodies
• Small Molecule Drug conjugates

Small molecules can further be classified as follows:

• Small molecule proteasome inhibitor (e.g. Bortezomib)
• Small molecule cyclin-dependent kinase inhibitor (e.g. Seliciclib)
• Small molecule tyrosine kinase inhibitor (e.g. Imatinib)

Geographically, North America is the leading market due to the rise incancer cases. According to the International Agency for Research on Cancer (IARC), around 13 million new cancer cases has been diagnosed worldwide. Moreover, according to the World Cancer Report, incidence rate of cancer could further rise by 50% to 15 million new cancer cases by 2020. Furthermore, the European and Asian-Pacific regions are expected to witness increased market traction due to commercialization of target oriented economic drugs.

Avail a Sample Copy: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2107

The major factors driving this market are rise in incidence rate of cancer, minimal adverse effects, targeted approach and high adoption rate. Additionally, more number of blockbuster drugs such as Novartis’s Glivec are losing their patents, leaving significant opportunities for manufacturers of targeted cancer drugs. However, high developmental costs, stringent regulatory policies andlow awareness are some of the restraints that could impede the growth of the market.

Some of the market players in this industry segment are Abbott Laboratories, Bayer HealthCare AG, Boehringer Ingelheim GmbH, CytokineticsInc., GlaxoSmithKline plc, Hospira Inc. , OncoGenex Pharmaceuticals Inc., and others.

Talks on the Future of Stem Cells - Trends and Innovations in Healthcare

As stem cells studies advance, stem cell therapy is looked upon as the go-to treatment option for a number of medical conditions. In a breakthrough development in stem cell studies, researchers at Massachusetts Institute of Technology (MIT) have developed a new programming technique that will allow the production of different types of tissues on-demand on a chip. Treatments for autoimmune diseases such as rheumatoid arthritis and growing tissues on-demand for organ replacement is not a faraway reality.

The global stem cells market is divided on the basis of product, application, technology, and

geography in this report. The research report provides historical and forecast analysis of market size, growth trends, and vital established and emerging growth areas in the global stem cells market. The report serves as a valuable guide for understanding the developments in the global stem cells market during the forecast period. Research data has been collated and presented in a crisp format. 

Using graphs and illustrations, the market study presents the current competitive landscape of the global stem cells market with changes in market hierarchy expected during the forecast period. The major companies that are involved in the business of stem cells are mentioned and are profiled for their key attributes.

Request a Sample copy of Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=132

Overview of Global Stem Cells Market    

The global stem cells market was valued at US$26.23 bn in 2013. Consistent research studies around the world to discover the potential of stem cells for the treatment of several medical conditions will lead the market to rise at a 24.2% CAGR from 2012 to 2018. Owing to this, the global stem cells market will be valued at US$119.52 bn by the end of 2018.

Some of the factors that are driving the global stem cells market are: a growing number of stem cell banks, government support for clinical research and stem cell therapy advancements boosting medical tourism for recuperative purposes, and unmet medical needs. 

Stem cells are undifferentiated cells that have the remarkable potential to differentiate into several cell types during the early period of growth. These cells can differentiate, either to function as a stem cell or to develop into another cell type with a more specialized function, such as a red blood cell, brain cell, or muscle cell.

By product type, adult, induced pluripotent, very small embryonic-like, human embryonic, and rat neural stem cells are the segments of this market. Of these, adult stem cells account for the largest market share due to a relatively easier procedure to harvest these cells and higher chances of acceptance by the body. Umbilical cord, neuronal, hematopoietic, dental, and mesenchymal are the sub-segments of the adult stem cells segment. Culture, in-vitro fertilization, expansion and sub-culture, isolation, and cryopreservation are the segments that divide the market on the basis of technology. Application-wise, neurology, oncology, cardiovascular, wound care, diabetes, incontinence, orthopedics, hematology, myocardial infarction, spinal cord injuries, liver disorders, and others are the segments of the global stem cells market.

Regional Analysis: http://www.tmrblog.com/2015/12/stem-cells-market.html

North America is a significant market for stem cells accounting for more than 25% of the global market in 2011.

Major Companies in Global Stem Cells Market

STEMCELL Technologies Inc., Biotime Inc., Cellular Engineering Technologies, Celgene Corporation Inc., Brainstorm Cell Therapeutics, Bioheart, Osiris Therapeutics, Cytori Therapeutics Inc., Cellartis AB, California Stem Cells Inc., Angel Biotechnology, and Advanced Cell